Special Issue "Advances in Anticancer Coordination Compounds"
A special issue of Crystals (ISSN 2073-4352).
Deadline for manuscript submissions: 31 August 2018
Prof. Dr. Salah Massoud
Department of Chemistry, University of Louisiana at Lafayette, Montgomery Hall, B. O. Box 44370, Lafayette, LA 70504-4370, USA
Website | E-Mail
Fax: +1 337 482 5676
Interests: bioinorganic chemistry: synthesis of anticancer metal complexes and efficient artificial nucleases to catalyze DNA cleavage and phosphodiesters; material science: syntheses of single and coordination polymers with interesting magnetic properties exhibiting slow relaxation magnetic (MMs and SIMs)
According to World Health Organization and a Cancer J. Clinicians (2016), cancer is the most common cause of death worldwide. It was responsible for 8.8 million deaths in 2015 (Lung: 1.69 million deaths; Liver: 788,000 deaths; Colorectal: 774,000 deaths; Stomach (754,000 deaths; Breast: 571,000 deaths). Each year, the American Cancer Society (CA Cancer J Clin 2016, 7–30 and American Cancer Society, 2015) statistically estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data. In 2016, the mortality data that were collected by the National Center for Health Statistics predicted 1,685,210 new cancer cases and 595,690 cancer deaths were projected to occur in the United States, and the former number is expected to rise to 15.1 million people in 2030. Despite good progress in the fight against cancer, death rates are increasing for certain kinds of cancers, such as the liver, pancreas, and uterine corpus. Cancer is now the leading cause of death in 21 states. Brain cancer has surpassed leukemia as the leading cause of cancer death in children and adolescents (aged birth-19 years) because of the dramatic therapeutic advances against leukemia.
Following all of the abovementioned points, more research and development for new metal-based drugs in cancer chemotherapy are urgently required. The success of anticancer drugs should include a wide spectrum of antitumor activity against drug-resistant, as well as drug sensitive, and exhibit activity against viral-induced, chemical-induced, and transplantable tumors. Additionally, they should show activity against slow-growing tumor and rapidly-growing tumors, as well as no strain or species specificity.
In the fight against cancer, many transition metal complexes have been launched for use as potential anticancer chemotherapeutic agents. However, cisplatin, as well as second and third generation platinum complexes (carboplatin, oxaliplatin, picoplatin, triplatin tetranitrate BBR3474), are the most effective antitumor agents. Additionally, from the widespread success of platinum complexes and, in particular, cisplatin being at the frontline in the fight against cancer, some major problems may arise from the use of these compounds, such as their toxicity (side effects), limited applications to some kinds of cancers and resistance exhibited by some carcinogenic tumor cells. In the last two decades, research efforts have been directed to the use of some other coordination compounds based on ruthenium(II/III), gold(I/III), gallium(III), titanium((III/IV) and iron(II/III) with different and sometime elegant ligands. Some of these compounds have been reported for preclinical or in clinical phase I and/or II. These problems have stimulated extensive searches to find an alternative different metal ion to improve the cytotoxicity and the pharmacological properties of the drug. More recently, copper (I/II) has been extensively investigated and emerged as an anticancer therapeutic agent. The choice of metal ion and the nature of coordinated ligands are considered to be crucial parameters in the success of any antitumor compound.
We invite investigators to submit papers that discuss the development, synthesis and characterization of metal complexes, including their potential anticancer activity of the compounds. This Special Issue of Crystals includes, but is not limited to, to any of the abovementioned metal ions and/or DNA cleavage, related to the title “Advances in Anticancer Coordination Compounds”.
Prof. Dr. Salah Massoud
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Crystals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Anticancer of Coordination Compounds